Vidupiprant, formerly known as AMG853, is a potent, selective orally bioavailable a dual D-prostanoid and CRTH2 inhibitor. Clinical trail results published on 2013 (J Allergy Clin Immunol. 2013 Feb;131(2):339-45) showed that AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma. References: Norman P. Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. doi: 10.1517/13543784.2013.839658. Epub 2013 Sep 27. Review. PubMed PMID: 24073896.

纯度：≥98%

CAS：1169483-24-2